AccidentalExpression
@BlogToWorld
Full Disclaimer: AccidentalExpression is Connecting People - Learn & Share, Not Financial Advise at all. Only for entertainment purpose. Please do your own DD.
You might like
😇🙏
$ocgn Hey fam. 👨🌾 Unsure, confused, curious? If so, listen to what I’m about to say closely, because I’m about to disclose something that only someone who’s followed this company for years would catch. Ocugen’s OCU400 Phase 3 for RP started dosing in June 2024. The narrative…
$OCGN #OCUGEN 👇 👇 👇 👇 She is amazing addition to the team! @Ocugen @drsmusunuri thank you for bringing top people on board 🙏
😇🙏
This week is #PatientRecognitionWeek. Hear from Aiden, an #OCU410ST Phase 1 participant diagnosed with #Stargardtdisease in high school. After treatment, he’s now experiencing positive changes in daily life and greater confidence. Hope begins here: bit.ly/3LSHivq
$ocgn great job fighting for the reauthorization. Congrats to you and the 12.5 to 15 million kids in the USA living with a rare disease. 👏
Wonderful news to see Congress pass legislation that reauthorizes the Rare Pediatric Disease Priority Review Voucher (PRV) program included in the Give Kids a Chance Act! #BIOTechCaucus #GiveKidsaChance
😇🙏
Wonderful news to see Congress pass legislation that reauthorizes the Rare Pediatric Disease Priority Review Voucher (PRV) program included in the Give Kids a Chance Act! #BIOTechCaucus #GiveKidsaChance
😇🙏
12-month Phase 1 data of #OCU410 for #geographicatrophy (GA) showed 60% slower ellipsoid zone loss and 20.2% reduction in GA lesion growth in treated eyes vs untreated eyes. Safety remains favorable with no serious adverse events reported. Read more: bit.ly/4k2YuuK
😇🙏
31 years after her #retinitispigmentosa diagnosis, Nancy is experiencing change through treatment in the #OCU400 clinical trial. She reports better definition, improved light adaptation, and can read without a magnifier. Modifier gene therapy: bit.ly/4bjhov5
$OCGN #OCUGEN #RTW Investments The more I look into today's news, the more I think there is a bigger story behind it...... jmo.
😇🙏
Patients join our clinical trials or EAP with a clear goal: to retain or improve vision. @davidalmeidaMD shares how we support patients and how our novel modifier gene therapies aim to address the entire disease with a single, one-time treatment. 📧[email protected]
I can’t help but think this will end up being a very big week for Ocugen. $OCGN Just something about the energy that feels… right.
Fierce Biotech Armada Results! fiercebiotech.com/biotech/ocugen…
fiercebiotech.com
Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas
Ocugen has reported preliminary phase 2 data on its e | Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform...
Thanks @drsmusunuri for what you do, millions of patients are desperately waiting. 🙏
Millions of patients with GA could see a potential new standard of care with OCU410, a one shot for life therapy. 46% reduction in lesion growth at just 12 months, versus existing approaches which generate ~22% reduction at 24 months and require 6-12 injections a year besides…
Ocugen shared positive 12-month Phase 2 data from ~50% of patients for #OCU410 in #GA, showing a 46% reduction in lesion growth vs. control and new Phase 1 data showing 60% slower EZ loss with no OCU410-related serious adverse events to date. Learn more: bit.ly/4sHl4Nb
$ocgn congrats, looks like we own the next standard of care for GA. 🍻 ir.ocugen.com/news-releases/…
💥💥💥💥Ocugen posts mid-stage trial data for GA therapy - Seeking Alpha stocks.apple.com/AUGlywDzBTlaHP…
$OCGN Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates finance.yahoo.com/news/why-narra…
$ocgn has secured 3 new US drug trademarks — something biotech companies usually do only 12–24 months before expected FDA approvals. This strongly suggests Ocugen is preparing its gene therapies for real commercial launches, not just clinical trials. $OCGN
They could literally drop further interim data to substantiate pipeline drug efficacy leading into Thursday. FDA potentially CNPV 🔬🧬🥼🌋 #OCU400 P2 - 2yr Evidenced P3 - Awaiting #OCU410ST P1 - Evidenced P2/3 Awaiting #OCU410GA P1/2 - Awaiting #OCU200 P1 - Awaiting $OCGN
Here is @davidrliu during the FDA’s Cell and Gene Therapy roundtable suggesting to establish “regulatory pathways that do not require 3 PPQ (Process Performance Qualification) runs at 7 million dollars a run”. It’s great to see the current FDA’s "Make American Biotech Accelerate"…
Ocugen to Reveal OCU410 Phase 2 Clinical Trial Data $OCGN, #Ocugen crweworld.com/article/news-p…
United States Trends
- 1. #mcnuggetcaviar N/A
- 2. Good Tuesday N/A
- 3. Anthony Bourdain N/A
- 4. Yayo N/A
- 5. Taco Tuesday N/A
- 6. #SayonaHijaDelMal N/A
- 7. #McDonalds N/A
- 8. Ja Rule N/A
- 9. #JUNGKOOKxHUBLOT N/A
- 10. Medicare N/A
- 11. #tuesdayvibe N/A
- 12. Lutnick N/A
- 13. Maracaibo N/A
- 14. Murda N/A
- 15. $Giraffes N/A
- 16. Wexner N/A
- 17. Rasmussen N/A
- 18. Ben Ogden N/A
- 19. Randy Fine N/A
- 20. John Q N/A
Something went wrong.
Something went wrong.